Effect of casting solvent, film-forming agent and solubilizer on orodispersible films of a polymorphic poorly soluble drug: an in vitro/in silico study

References

• Rahma NS. Drug delivery: oral route. In: Swarbrick J, editor. Encyclopedia of pharmaceutical science and technology. 4th ed. Boka Raton: Taylor & Francis; 2013. p. 1122–1149.
   Google Scholar
• Nagaraju T, Gowthami R, Rajashekar M, et al. Comprehensive review on oral disintegrating films. Curr Drug Del. 2013;10:96–108.
   PubMed Web of Science ®Google Scholar
• Dixit RP, Puthli SP. Oral strip technology: overview and future potential. J Control Release. 2009;139:94–107.
   PubMed Web of Science ®Google Scholar
• Visser JC, Woerdenbag HJ, Hanff LM, et al. Personalized medicine in pediatrics: the clinical potential of orodispersible films [journal article]. AAPS PharmSciTech. 2017;18:267–272.
   PubMed Web of Science ®Google Scholar
• Bala R, Pawar P, Khanna S, et al. Orally dissolving strips: a new approach to oral drug delivery system. Int J Pharma Investig. 2013;3:67–76.
   PubMedGoogle Scholar
• Krampe R, Visser JC, Frijlink HW, et al. Oromucosal film preparations: points to consider for patient centricity and manufacturing processes. Expert Opin Drug Deliv. 2016;13:493–506.
   PubMed Web of Science ®Google Scholar
• Borges AF, Silva C, Coelho JFJ, et al. Oral films: current status and future perspectives: I-Galenical development and quality attributes. J Control Release. 2015;206:1–19.
   PubMed Web of Science ®Google Scholar
• Council of Europe. European Pharmacopoeia. 8th ed. Strasbourg: Council of Europe; 2014.
   Google Scholar
• In-PharmaTechnologist.com. Zengen claims a first with drug-laden oral strip France: William Reed Business Media SAS; 2003. [cited 2017 July 23]. Available from: http://www.in-pharmatechnologist.com/Processing/Zengen-claims-a-first-with-drug-laden-oral-strip.
   Google Scholar
• In-PharmaTechnologist.com. Novartis launches first systemic OTC in film strip format France: William Reed Business Media SAS; 2004. [cited 2017 July 23]. Available from: http://www.in-pharmatechnologist.com/Ingredients/Novartis-launches-first-systemic-OTC-in-film-strip-format
   Google Scholar
• Saigal N, Baboota S, Ahuja A, et al. Fast-dissolving intra-oral drug delivery systems. Expert Opin Ther Pat. 2008;18:769–781.
   Web of Science ®Google Scholar
• Krull SM, Ammirata J, Bawa S, et al. Critical material attributes of strip films loaded with poorly water-soluble drug nanoparticles: II. Impact of polymer molecular weight. J Pharm Sci. 2017;106:619–628.
   PubMed Web of Science ®Google Scholar
• Sayed S, Ibrahim HK, Mohamed MI, et al. Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation. Mol Pharmaceutics. 2013;10:2942–2947.
   PubMed Web of Science ®Google Scholar
• Deepthi A, Reddy BV, Navaneetha K. Formulation and evaluation of fast dissolving oral films of zolmitriptan. Am J Adv Drug Deliv. 2014;2:153–163.
   Google Scholar
• Mahesh A, Shastri N, Sadanandam M. Development of taste masked fast disintegrating films of levocetirizine dihydrochloride for oral use. CDD. 2010;7:21–27.
   PubMedGoogle Scholar
• Schobel AM, Vangala SS, inventors; Google Patents, assignee. Solid dosage form containing a taste masked active agent patent US20070292515A1. 2015.
   Google Scholar
• Liew KB, Tan YTF, Peh KK. Effect of polymer, plasticizer and filler on orally disintegrating film. Drug Dev Ind Pharm. 2014;40:110–119.
   PubMed Web of Science ®Google Scholar
• Krull SM, Patel HV, Li M, et al. Critical material attributes (CMAs) of strip films loaded with poorly water-soluble drug nanoparticles: I. Impact of plasticizer on film properties and dissolution. Eur J Pharm Sci. 2016;92:146–155.
   PubMed Web of Science ®Google Scholar
• Jain D, Bar-Shalom D. Alginate drug delivery systems: application in context of pharmaceutical and biomedical research. Drug Dev Ind Pharm. 2014;40:1576–1584.
   PubMed Web of Science ®Google Scholar
• Shelke PV, Dumbare A, Gadhave M, et al. Formulation and evaluation of rapidly disintegrating film of amlodipine besylate. J Drug Delivery Ther. 2012;2:72–75.
   Google Scholar
• Preis M, Woertz C, Kleinebudde P, et al. Oromucosal film preparations: classification and characterization methods. Expert Opin Drug Deliv. 2013;10:1303–1317.
   PubMed Web of Science ®Google Scholar
• Kraemer J, Gajendran J, Guillot A, et al. Dissolution testing of orally disintegrating tablets. J Pharm Pharmacol. 2012;64:911–918.
   PubMed Web of Science ®Google Scholar
• Shohin IE, Kulinich JI, Ramenskaya GV, et al. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam. J Pharm Sci. 2014;103:367–377.
   PubMed Web of Science ®Google Scholar
• Okuyama H, Ikeda Y, Kasai S, et al. Influence of non-ionic surfactants, pH and propylene glycol on percutaneous absorption of piroxicam from cataplasm. Int J Pharm. 1999;186:141–148.
   PubMedGoogle Scholar
• Jinno J, Oh D-M, Crison JR, et al. Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. J Pharm Sci. 2000;89:268–274.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Chakraborty H, Sarkar M. Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam. Spectrochimica Acta A Mol Biomol Spectrosc. 2003;59:1213–1222.
   PubMed Web of Science ®Google Scholar
• Pliska V, Testa B, van de Waterbeemd H, et al. Lipophilicity in drug action and toxicology. Weinheim: VCH Publishers; 1996.
   Google Scholar
• Paaver U, Lust A, Mirza S, et al. Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. Int J Pharm. 2012;431:111–119.
   PubMed Web of Science ®Google Scholar
• Taniguchi C, Kawabata Y, Wada K, et al. Microenvironmental pH-modification to improve dissolution behavior and oral absorption for drugs with pH-dependent solubility. Expert Opin Drug Deliv. 2014;11:505–516.
   PubMed Web of Science ®Google Scholar
• Mihalic M, Hofman H, Kajfez F, et al. Physicochemical and analytical characteristics of piroxicam. Acta Pharm Jugosl. 1982;32:13–20.
   Google Scholar
• Lavrič Z, Pirnat J, Lužnik J, et al. 14N Nnuclear quadrupole resonance study of piroxicam: confirmation of new polymorphic form V. J Pharm Sci. 2015;104:1909–1918.
   PubMed Web of Science ®Google Scholar
• Nyström M, Roine J, Murtomaa M, et al. Solid state transformations in consequence of electrospraying – a novel polymorphic form of piroxicam. Eur J Pharm Biopharm. 2015;89:182–189.
   PubMed Web of Science ®Google Scholar
• Lyn L, Sze H, Rajendran A, et al. Crystal modifications and dissolution rate of piroxicam. Acta Pharmaceutica. 2011;61:391–402.
   PubMed Web of Science ®Google Scholar
• Dumortier G, Grossiord J, Agnely F, et al. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23:2709–2728.
   PubMed Web of Science ®Google Scholar
• ISO 9276-6:2008. Representation of results of particle size analysis - Part 6: Descriptive and quantitative representation of particle shape and morphology. Geneva, Switzerland: International Organization for Standardization; 2008.
   Google Scholar
• ASTM D624-00(2012). Standard test method for tear strength of conventional vulcanized rubber and thermoplastic elastomers. West Conshohocken (PA): ASTM International; 2012.
   Google Scholar
• Mitchell J. Jr Methods for the determination of water in polymers. Anal Chim Acta. 1976;81:231–263.
   Web of Science ®Google Scholar
• Tran PL, Tran TTD, Lee KH, et al. Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility. Expert Opin Drug Deliv. 2010;7:647–661.
   PubMed Web of Science ®Google Scholar
• Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48–49.
   PubMed Web of Science ®Google Scholar
• Harland RS, Dubernet C, Benoît J-P, et al. A model of dissolution-controlled, diffusional drug release from non-swellable polymeric microspheres. J Control Release. 1988;7:207–215.
   Web of Science ®Google Scholar
• Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149.
   PubMed Web of Science ®Google Scholar
• Mitchell JS. The role of molecular orientation in photochemical reactions in monolayers. J Chem Phys. 1936;4:725–730.
   Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5:37–42.
   Google Scholar
• Ahuja N, Katare OP, Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm. 2007;65:26–38.
   PubMed Web of Science ®Google Scholar
• De Brabander C, Vervaet C, Remon JP. Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion. J Control Release. 2003;89:235–247.
   PubMed Web of Science ®Google Scholar
• Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20:64–74.
   Google Scholar
• Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Del Rev. 2001;50:S41–S67.
   PubMed Web of Science ®Google Scholar
• Tubic-Grozdanis M, Bolger MB, Langguth P. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J. 2008;10:213–226.
   PubMed Web of Science ®Google Scholar
• Stulzer HK, Tagliari MP, Cruz AP, et al. Compatibility studies between piroxicam and pharmaceutical excipients used in solid dosage forms. Pharm Chem J. 2008;42:215–219.
   Google Scholar
• Varshosaz J, Khajavinia A, Ghasemlu M, et al. Enhancement in dissolution rate of piroxicam by two micronization techniques. Dissolution Technol. 2013;20:15–23.
   Web of Science ®Google Scholar
• Soares JP, Santos JE, Chierice GO, et al. Thermal behavior of alginic acid and its sodium salt. Eclet Quím. 2004;29:57–63.
   Google Scholar
• Mura P, Bettinetti GP, Cirri M, et al. Solid-state characterization and dissolution properties of naproxen–arginine–hydroxypropyl-β-cyclodextrin ternary system. Eur J Pharm Biopharm. 2005;59:99–106.
   PubMed Web of Science ®Google Scholar
• Vrecˇer F, Srcˇicˇ S, Sˇmid-Korbar J. Investigation of piroxicam polymorphism. Int J Pharm. 1991;68:35–41.
   Web of Science ®Google Scholar
• Lai F, Pini E, Angioni G, et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur J Pharm Biopharm. 2011;79:552–558.
   PubMed Web of Science ®Google Scholar
• Hansen TB, Qu H. Formation of piroxicam polymorphism in solution crystallization: effect and interplay of operation parameters. Crystal Growth Design. 2015;15:4694–4700.
   Web of Science ®Google Scholar
• ElMeshad A, El Hagrasy A. Characterization and optimization of orodispersible mosapride film formulations. AAPS PharmSciTech. 2011;12:1384–1392.
   PubMed Web of Science ®Google Scholar
• Beck C, Sievens-Figueroa L, Gärtner K, et al. Effects of stabilizers on particle redispersion and dissolution from polymer strip films containing liquid antisolvent precipitated griseofulvin particles. Powder Technol. 2013;236:37–51.
   Web of Science ®Google Scholar
• Krull SM, Susarla R, Afolabi A, et al. Polymer strip films as a robust, surfactant-free platform for delivery of BCS Class II drug nanoparticles. Int J Pharm. 2015;489:45–57.
   PubMed Web of Science ®Google Scholar
• Timmins P, Pygall SR, Melia CD. Hydrophilic matrix tablets for oral controlled release. New York (NY): Springer; 2014.
   Google Scholar
• Warren DB, Benameur H, Porter CJH, et al. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility. J Drug Target. 2010;18:704–731.
   PubMed Web of Science ®Google Scholar
• Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert Opin Drug Deliv. 2011;8:299–316.
   PubMed Web of Science ®Google Scholar
• Krull SM, Ma Z, Li M, et al. Preparation and characterization of fast dissolving pullulan films containing BCS class II drug nanoparticles for bioavailability enhancement. Drug Dev Ind Pharm. 2016;42:1073–1085.
   PubMed Web of Science ®Google Scholar
• Visser JC, Dohmen WMC, Hinrichs WLJ, et al. Quality by design approach for optimizing the formulation and physical properties of extemporaneously prepared orodispersible films. Int J Pharm. 2015;485:70–76.
   PubMed Web of Science ®Google Scholar
• Visser JC, Woerdenbag HJ, Crediet S, et al. Orodispersible films in individualized pharmacotherapy: The development of a formulation for pharmacy preparations. Int J Pharm. 2015;478:155–163.
   PubMed Web of Science ®Google Scholar
• Tran PHL, Tran HTT, Lee BJ. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release. 2008; 129:59–65.
   PubMed Web of Science ®Google Scholar
• Arakawa T, Kita Y, Koyama AH. Solubility enhancement of gluten and organic compounds by arginine. Int J Pharm. 2008;355:220–223.
   PubMed Web of Science ®Google Scholar
• Hirano A, Kameda T, Arakawa T, et al. Arginine-assisted solubilization system for drug substances: solubility experiment and simulation. J Phys Chem B. 2010;114:13455–13462.
   PubMed Web of Science ®Google Scholar
• Ha NS, Tran TT-D, Tran P-L, et al. Dissolution-enhancing mechanism of alkalizers in poloxamer-based solid dispersions and physical mixtures containing poorly water-soluble valsartan. Chem Pharm Bull. 2011;59:844–850.
   PubMed Web of Science ®Google Scholar
• Preis M, Gronkowsky D, Grytzan D, et al. Comparative study on novel test systems to determine disintegration time of orodispersible films. J Pharm Pharmacol. 2014;66:1102–1111.
   PubMed Web of Science ®Google Scholar
• Dissolution methods. United States: FDA; 2015. [updated 2015 Nov 19]. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/index.cfm.
   Google Scholar
• Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm. 2002;28:621–630.
   PubMed Web of Science ®Google Scholar
• Mahjour M, Kesisoglou F, Cruanes M, et al. Effect of added alkalizer and surfactant on dissolution and absorption of the potassium salt of a weakly basic poorly water-soluble drug. J Pharm Sci. 2014;103:1811–1818.
   PubMed Web of Science ®Google Scholar
• Marasini N, Tran TH, Poudel BK, et al. Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique. Int J Pharm. 2013;441:424–432.
   PubMed Web of Science ®Google Scholar
• Patel JR, Carlton RA, Yuniatine F, et al. Preparation and structural characterization of amorphous spray-dried dispersions of tenoxicam with enhanced dissolution. J Pharm Sci. 2012;101:641–663.
   PubMed Web of Science ®Google Scholar
• Qi X, Zhang J, Wang W, et al. Solubility and stability of indomethacin in arginine-assisted solubilization system. Pharm Dev Technol. 2013;18:852–855.
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, et al. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.
   Web of Science ®Google Scholar
• Kovačević I, Parojčić J, Homšek I, et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharmaceutics. 2009;6:40–47.
   PubMed Web of Science ®Google Scholar
• Honório dTS, Pinto EC, Rocha HVA, et al. In vitro–in vivo correlation of efavirenz tablets using GastroPlus® [journal article]. AAPS PharmSciTech. 2013;14:1244–1254.
   PubMed Web of Science ®Google Scholar
• Duque MD. Determination of absorption curves, dissolution profiles and establishment of in vitro-in vivo correlation by in silico methods using GastroPlusTM and DDDPlusTM. São Paulo: University of São Paulo; 2016.
   Google Scholar
• Tsume Y, Langguth P, Garcia-Arieta A, et al. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm Drug Dispos. 2012;33:366–377.
   PubMed Web of Science ®Google Scholar
• Jiang W, Kim S, Zhang X, et al. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm. 2011;418:151–160.
   PubMed Web of Science ®Google Scholar
• Helmy SA, El-Bedaiwy HM. Piroxicam immediate release formulations: a fasting randomized open-label crossover bioequivalence study in healthy volunteers. Clin Pharmacol Drug Develop. 2014;3:466–471.
   PubMed Web of Science ®Google Scholar
• Piscitelli DA, Bigora S, Propst C, et al. The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. Pharm Develop Technol. 1998;3:443–452.
   PubMedGoogle Scholar
• Rasetti-Escargueil C, Grangé V. Pharmacokinetic profiles of two tablet formulations of piroxicam. Int J Pharm. 2005;295:129–134.
   PubMedGoogle Scholar
• Woolf AD, Rogers HJ, Bradbrook ID, et al. Pharmacokinetic observations on piroxicam in young adult, middle-aged and elderly patients. Br J Clin Pharmacol. 1983;16:433–437.
   PubMed Web of Science ®Google Scholar
• FDA Guidance for Industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs-General considerations. 2014. Available from: https://www.fda.gov/media/88254/download.
   Google Scholar
•  European Medicines Agency. CPMP/EWP/QWP/1401/98. Rev.1. Guideline on the investigation of bioequivalence. 2010. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf.
   Google Scholar
• Okumu A, DiMaso M, Löbenberg R. Computer simulations using GastroPlus™ to justify a biowaiver for etoricoxib solid oral drug products. Eur J Pharm Biopharm. 2009;72:91–98.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhou H, Seitz K, et al. Bioavailability and bioequivalence. In: Chen Y, Zhang GGZ, Liu L, editors. Developing solid oral dosage forms. San Diego (CA): Academic Press; 2009. p. 341–364.
   Google Scholar
• Takamatsu N, Welage LS, Idkaidek NM, et al. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res. 1997;14:1127–1132.
   PubMed Web of Science ®Google Scholar
• Kortejärvi H, Urtti A, Yliperttula M. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. Eur J Pharm Sci. 2007;30:155–166.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Yazdanian M, Briggs K, Jankovsky C, et al. The “High Solubility” definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res. 2004;21:293–299.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL, Polli JE, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19:921–925.
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fortieth Report. Geneva; 2006. (WHO Technical Report Series; 937). Available from: https://apps.who.int/medicinedocs/documents/s14091e/s14091e.pdf.
   Google Scholar
• Dressman J, Butler J, Hempenstall J, et al. The BCS: where do we go from here? Pharm Technol. 2001;25:68–77.
   Google Scholar
• Dressman JB, Amidon GL, Reppas C, et al. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11–22.
   PubMed Web of Science ®Google Scholar
• Parrott N, Lukacova V, Fraczkiewicz G, et al. Predicting pharmacokinetics of drugs using physiologically based modeling-application to food effects. AAPS J. 2009;11:45–53.
   PubMed Web of Science ®Google Scholar